Daniel A.J. Bow

796 total citations
17 papers, 604 citations indexed

About

Daniel A.J. Bow is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Infectious Diseases. According to data from OpenAlex, Daniel A.J. Bow has authored 17 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pediatrics, Perinatology and Child Health and 6 papers in Infectious Diseases. Recurrent topics in Daniel A.J. Bow's work include Drug Transport and Resistance Mechanisms (12 papers), HIV/AIDS drug development and treatment (6 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Daniel A.J. Bow is often cited by papers focused on Drug Transport and Resistance Mechanisms (12 papers), HIV/AIDS drug development and treatment (6 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Daniel A.J. Bow collaborates with scholars based in United States, Sweden and Switzerland. Daniel A.J. Bow's co-authors include Kim L. R. Brouwer, Jennifer L. Perry, John B. Pritchard, Ryota Kikuchi, Sonia M. de Morais, Dietrich Keppler, Johan Palm, Yurong Lai, Yaofeng Cheng and Keith Hoffmaster and has published in prestigious journals such as Accounts of Chemical Research, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Daniel A.J. Bow

17 papers receiving 595 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel A.J. Bow United States 12 407 226 191 106 74 17 604
Tom De Bruyn Belgium 12 386 0.9× 163 0.7× 217 1.1× 117 1.1× 62 0.8× 35 647
Grace Chan United States 14 444 1.1× 250 1.1× 194 1.0× 114 1.1× 107 1.4× 18 720
Jenny M. Pedersen Sweden 8 590 1.4× 292 1.3× 221 1.2× 142 1.3× 84 1.1× 11 754
Vaishali Dixit United States 11 247 0.6× 126 0.6× 229 1.2× 132 1.2× 115 1.6× 18 579
Gunilla Englund Sweden 6 436 1.1× 207 0.9× 124 0.6× 109 1.0× 66 0.9× 6 608
Rucha Sane United States 14 305 0.7× 151 0.7× 284 1.5× 151 1.4× 124 1.7× 36 713
Agnès Poirier Switzerland 14 521 1.3× 303 1.3× 306 1.6× 254 2.4× 81 1.1× 21 886
Sarah Shugarts United States 9 259 0.6× 119 0.5× 134 0.7× 130 1.2× 76 1.0× 13 691
Émilie Jigorel France 6 410 1.0× 165 0.7× 250 1.3× 115 1.1× 46 0.6× 6 593
Robert A.B. van Waterschoot Netherlands 16 725 1.8× 233 1.0× 419 2.2× 332 3.1× 73 1.0× 20 1.2k

Countries citing papers authored by Daniel A.J. Bow

Since Specialization
Citations

This map shows the geographic impact of Daniel A.J. Bow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A.J. Bow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A.J. Bow more than expected).

Fields of papers citing papers by Daniel A.J. Bow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A.J. Bow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A.J. Bow. The network helps show where Daniel A.J. Bow may publish in the future.

Co-authorship network of co-authors of Daniel A.J. Bow

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A.J. Bow. A scholar is included among the top collaborators of Daniel A.J. Bow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A.J. Bow. Daniel A.J. Bow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Savaryn, John P., R. Kikuchi, Yuli Qian, et al.. (2024). Endogenous plasma riboflavin is not a viable BCRP biomarker in human. Clinical and Translational Science. 17(12). e70109–e70109. 2 indexed citations
2.
Kikuchi, Ryota, William J. Chiou, Kenneth R. Durbin, et al.. (2021). Quantitation of Plasma Membrane Drug Transporters in Kidney Tissue and Cell Lines Using a Novel Proteomic Approach Enabled a Prospective Prediction of Metformin Disposition. Drug Metabolism and Disposition. 49(10). 938–946. 7 indexed citations
3.
Randolph, John T., Tongmei Li, A. Chris Krueger, et al.. (2020). Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(7). 126986–126986. 3 indexed citations
4.
Kalluri, Hari V., Ryota Kikuchi, Jeffrey M. Schmidt, et al.. (2020). Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study. Clinical and Translational Science. 14(1). 373–381. 23 indexed citations
5.
Randolph, John T., Eric A. Voight, Stephen N. Greszler, et al.. (2020). Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). Journal of Medicinal Chemistry. 63(19). 11034–11044. 11 indexed citations
6.
Kosloski, Matthew P., Daniel A.J. Bow, Ryota Kikuchi, et al.. (2019). Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. Journal of Pharmacology and Experimental Therapeutics. 370(2). 278–287. 16 indexed citations
7.
Kikuchi, Ryota, et al.. (2019). No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat. Journal of Pharmaceutical Sciences. 108(9). 3118–3123. 5 indexed citations
8.
Riedmaier, Arian Emami, David Lindley, Jeffrey A. Hall, et al.. (2017). Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound—The Venetoclax Story. Journal of Pharmaceutical Sciences. 107(1). 495–502. 58 indexed citations
9.
Shebley, Mohamad, Jinrong Liu, Jens Sydor, et al.. (2017). Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir. Drug Metabolism and Disposition. 45(7). 755–764. 33 indexed citations
10.
Kikuchi, Ryota, Mohamad Shebley, Daniel A.J. Bow, et al.. (2017). In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug-drug interaction assessment for venetoclax. Drug Metabolism and Pharmacokinetics. 32(1). S51–S51. 6 indexed citations
11.
Kikuchi, Ryota, Vincent Peterkin, William J. Chiou, Sonia M. de Morais, & Daniel A.J. Bow. (2016). Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions. Xenobiotica. 47(9). 825–832. 11 indexed citations
12.
Chiou, William J., Sonia M. de Morais, Ryota Kikuchi, et al.. (2013). In vitroOATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica. 44(3). 276–282. 34 indexed citations
13.
Kikuchi, Ryota, Yanbin Lao, Daniel A.J. Bow, et al.. (2013). Prediction of Clinical Drug–Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). Journal of Pharmaceutical Sciences. 102(12). 4426–4432. 51 indexed citations
14.
Brouwer, Kim L. R., Dietrich Keppler, Keith Hoffmaster, et al.. (2013). In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development. Clinical Pharmacology & Therapeutics. 94(1). 95–112. 191 indexed citations
15.
Bow, Daniel A.J., Jennifer L. Perry, David S. Miller, John B. Pritchard, & Kim L. R. Brouwer. (2007). Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in Freshly Isolated Rat Hepatocytes. Drug Metabolism and Disposition. 36(1). 198–202. 87 indexed citations
16.
Bow, Daniel A.J., Jennifer L. Perry, John D. Simon, & John B. Pritchard. (2005). The Impact of Plasma Protein Binding on the Renal Transport of Organic Anions. Journal of Pharmacology and Experimental Therapeutics. 316(1). 349–355. 35 indexed citations
17.
Dai, Jian, Gyungse Park, Jennifer L. Perry, et al.. (2004). Molecular Aspects of the Transport and Toxicity of Ochratoxin A. Accounts of Chemical Research. 37(11). 874–881. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tom De Bruyn Breakdown of academic impact, for papers by Grace Chan Breakdown of academic impact, for papers by Jenny M. Pedersen Breakdown of academic impact, for papers by Vaishali Dixit Breakdown of academic impact, for papers by Gunilla Englund Breakdown of academic impact, for papers by Rucha Sane Breakdown of academic impact, for papers by Agnès Poirier Breakdown of academic impact, for papers by Sarah Shugarts Breakdown of academic impact, for papers by Émilie Jigorel Breakdown of academic impact, for papers by Robert A.B. van Waterschoot
Rankless by CCL
2026